Evidence map›Paper›PMID 35943667›Full record

ArticleClinical rheumatology2023

Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.

Michaël Doumen, Delphine Bertrand, Sofia Pazmino, Diederik De Cock, Veerle Stouten, Johan Joly, Isabelle de Wergifosse, Anneleen Moeyersoons, René Westhovens, Patrick Verschueren

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Michaël Doumen *Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. michael.doumen@kuleuven.be.ORCID http://orcid.org/0000-0001-6073-7635
Delphine Bertrand *Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Sofia PazminoDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Diederik De CockDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Veerle StoutenDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Johan JolyDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Isabelle de WergifosseReuma Instituut Hasselt, Hasselt, Belgium.
Anneleen MoeyersoonsVITAZ Sint-Niklaas Moerland, Sint-Niklaas, Belgium.
René WesthovensDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Patrick VerschuerenDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
KU Leuven · BEFlanders Marine Institute · BESciensano (Belgium) · BEVlaamse Vereniging voor Obstetrie en Gynaecolo · BEVrije Universiteit Brussel · BE

Funding

Fonds Wetenschappelijk Onderzoek 1S85521N
6 · The paper itself

Abstract

Flare Assessment in Rheumatoid Arthritis (FLARE-RA) is a self-administered tool aiming to capture current or recent flares in rheumatoid arthritis (RA). We aimed to externally validate the FLARE-RA instrument and its existing cutoffs for flare detection within a bDMARD-tapering context in established RA. Data were analyzed from the Tapering Etanercept in Rheumatoid Arthritis (TapERA) trial, which studied the feasibility of tapering etanercept in patients with established RA in sustained remission. The English FLARE-RA was translated and cross-culturally adapted into Dutch, and internal consistency and test-retest reliability were evaluated with Crohnbach's alpha and intraclass correlation coefficient (ICC). Participants completed the FLARE-RA 3-monthly for 12 months. Accuracy and optimal cutoffs of FLARE-RA to detect DAS28-defined flares were assessed using area under the receiver operating characteristic curves (AUC). Association of FLARE-RA scores with current and future flares was studied using logistic generalized estimating equations (GEE). The Dutch FLARE-RA showed excellent internal consistency and test-retest reliability (Cronbach's alpha 0.96; ICC 0.96 [95% CI 0.70-1.00]). Discriminatory capacity of FLARE-RA to detect flares was acceptable (AUC 0.77, 0.80, and 0.72 for global, arthritis, and general symptoms subscales, respectively), with an optimal global score cutoff of 4/10. In GEE-models, higher FLARE-RA scores were associated with increased odds of both current and future flares. We successfully translated and cross-culturally adapted the FLARE-RA into a Dutch version and validated its capacity to detect flares in a bDMARD-tapering context in established RA. Finally, higher FLARE-RA scores might indicate an increased risk of future flares.Trial registration: EU Clinical Trials Register, https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004631-22/BE , EudraCT number 2012-004,631-22. Key Points • Translation and cross-cultural adaptation of the FLARE-RA resulted in a Dutch version with excellent internal consistency and test-retest reliability. • The FLARE-RA is a valid instrument to detect current OMERACT-defined flares within a bDMARD tapering setting, with an optimal global score cutoff of 4/10. • Higher scores on the FLARE-RA are associated with increased risk of future flares, which could be particularly relevant when considering DMARD tapering.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidEtanerceptHumansReproducibility of ResultsSeverity of Illness IndexSurveys and QuestionnairesAntirheumatic AgentsEtanerceptbDMARDsFlaresPatient-reported outcomesRheumatoid arthritisTaperingTNF-inhibitors

Identifiers

PMID35943667
OpenAlexW4290791271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.